Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 3/2011

01-09-2011 | Original Paper

Alterations of telomere length in human brain tumors

Authors: Majid Kheirollahi, Masoud Mehrazin, Naser Kamalian, Parvin Mehdipour

Published in: Medical Oncology | Issue 3/2011

Login to get access

Abstract

Telomeres at the ends of human chromosomes consist of tandem hexametric (TTAGGG)n repeats, which protect them from degradation. At each cycle of cell division, most normal somatic cells lose approximately 50–100 bp of the terminal telomeric repeat DNA. Precise prediction of growth and estimation of the malignant potential of brain tumors require additional markers. DNA extraction was performed from the 51 frozen tissues, and a non-radioactive chemiluminescent assay was used for Southern blotting. One sample t-test shows highly significant difference in telomere length in meningioma and astrocytoma with normal range. According to our results, higher grades of meningioma and astrocytoma tumors show more heterogeneity in telomere length, and also it seems shortening process of telomeres is an early event in brain tumors.
Literature
1.
Blackburn EH. Structure and function of telomeres. Nature. 1991;1350:569–73.CrossRef
2.
Counter CM, Avilion AA, LeFeuvre CE. Telomerase shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 1992;11:1921–9.PubMed
3.
Sandell LL, Zakian VA. Lost of a yeast telomere: arrest, recovery and chromosome loss. Cell. 1993;75:729–39.PubMedCrossRef
4.
Moyzis RK, Buckingham JM, Carm LS, Dani M, Deaven LL, Jones MD. A highly repetitive sequence (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci USA. 1988;85:6622–6.PubMedCrossRef
5.
Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature (Lond). 1990;345:458–60.CrossRef
6.
Levy MZ, Allsopp RC, Futcher AB, Greider CW, Harley CB. Telomere end-duplication problem and cell aging. J Mol Biol. 1992;225:951–60.PubMedCrossRef
7.
Surralles J, Hande MP, Marcos R, Lansdorp PM. Accelerated telomere shortening in the human inactive X chromosome. Am J Hum Genet. 1999;65:1617–22.PubMedCrossRef
8.
Lansdorp PM, Verwoerd NP, Rijke FM, Dragowska V, Little MT, Dirks RW. Heterogeneity in telomere length of human chromosomes. Human Mol Genet. 1995;5(5):685–91.CrossRef
9.
Greider CW. Telomerase activity, cell proliferation, and cancer. Proc Natl Acad Sci USA. 1998;95:90–2.PubMedCrossRef
10.
Harrington L, McPhail T, Mar V, Zhou W, Oulton R, Bass MB, et al. A mammalian telomerase-associated protein. Science. 1997;275:973–7.PubMedCrossRef
11.
Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25:585–621.CrossRef
12.
Kleihues P, Burger P, Scheithauer BW. Histological typing of tumours of the central nervous system (International histological classification of tumours). 2nd ed. Berlin: Springer; 1993.
13.
Hiraga S, Ohnishi T, Izumoto S, Miyahara E, Kanemura Y, Matsumura H, et al. Telomerase activity and alterations in telomere length in human brain tumors. Cancer Res. 1998;58:2117–25.PubMed
14.
Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol. 1993;3(3):255–68.PubMedCrossRef
15.
Tatter SB, Wilson CB, Harsh GRIV. Neuroepithelial tumors of the adult brain. 4th ed. Philadelphia: W.B. Saunders Co; 1995.
16.
Allsopp R, Chang E, Kashefi-Aazam M, Rogaev EI, Piatyszek MA, Shay JW, et al. Telomere shortening is associated with cell division in vitro and in vivo. Exp Cell Res. 1995;220:194–200.PubMedCrossRef
17.
Harley CB, Villeponteau B. Telomeres and telomerase in aging and cancer. Curr Opin Genet Dev. 1995;5:249–55.PubMedCrossRef
18.
19.
Bisoffi M, Heaphy CM, Griffith JK. Telomeres: prognostic markers for solid tumors. Int J Cancer. 2006;119:2255–60.PubMedCrossRef
20.
Svenson U, Roos G. Telomere length as a biological marker in malignancy. Biochim Biophys Acta. 2009;1792:317–23.PubMed
21.
Griffith JK, Bryant JE, Fordyce CA, Gilliland FD, Joste NE, Moyzis RK. Reduced telomere DNA content is correlated with genomic instability and metastasis in invasive human breast carcinoma. Breast Cancer Res Treat. 1999;54:59–64.PubMedCrossRef
22.
Fordyce CA, Heaphy CM, Bisoffi M, Wyaco JL, Joste NE, Mangalik A, et al. Telomere content correlates with stage and prognosis in breast cancer. Breast Cancer Res Treat. 2006;99:193–202.PubMedCrossRef
23.
Heaphy CM, Baumgartner KB, Bisoffi M, Baumgartner RN, Griffith JK. Telomere DNA content predicts breast cancer-free survival interval. Clin Cancer Res. 2007;13:7037–43.PubMedCrossRef
24.
Donaldson L, Fordyce C, Gilliland F, Smith A, Feddersen R, Joste N, et al. Association between outcome and telomere DNA content in prostate cancer. J Urol. 1999;162:1788–92.PubMedCrossRef
25.
Fordyce CA, Heaphy CM, Joste NE, Smith AY, Hunt WC, Griffith JK. Association between cancer-free survival and telomere DNA content in prostate tumors. J Urol. 2005;173:610–4.PubMedCrossRef
26.
Avigad S, Naumov I, Ohali A, Jeison M, Berco GH, Mardoukh J, et al. Short telomeres: a novel potential predictor of relapse in Ewing sarcoma. Clin Cancer Res. 2007;13:5777–83.PubMedCrossRef
27.
Gertler R, Rosenberg R, Stricker D, Friederichs J, Hoos A, Werner M, et al. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol. 2004;22:1807–14.PubMedCrossRef
28.
Oh BK, Kim H, Park YN, Yoo JE, Choi J, Kim KS, et al. High telomerase activity and long telomeres in advanced hepatocellular carcinomas with poor prognosis. Lab Invest. 2008;88:144–52.PubMedCrossRef
29.
Garcia-Aranda C, Juan CD, Diaz-Lopez A, Sanchez-Pernaute A, Torres AJ, Diaz-Rubio E, et al. Correlations of telomere length, telomerase activity, and telomeric-repeat binding factor 1 expression in colorectal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;106:541–51.
30.
Gertler R, Doll D, Maak M, Feith M, Rosenberg R. Telomere length and telomerase subunits as diagnostic and prognostic biomarkers in Barrett carcinoma. Cancer Epidemiol Biomarkers Prev. 2008;112:2173–80.
31.
Patel MM, Parekh LJ, Jha FP, Sainger RN, Patel JB, Patel DD, et al. Clinical usefulness of telomerase activation and telomere length in head and neck cancer. Head Neck. 2002;24:1060–7.PubMedCrossRef
32.
Wu X, Amos CI, Zhu Y, Zhao H, Grossman BH, Shay JW. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst. 2003;95(16):1211–8.PubMedCrossRef
33.
Ohali A, Avigad S, Ash S, Goshen Y, Luria D, Feinmesser M, et al. Telomere length is a prognostic factor in neuroblastoma. Cancer. 2006;107:1391–9.PubMedCrossRef
34.
Hiyama E, Hiyama K, Yokoyama T, Ichikawa T, Matsuura Y. Length of telomeric repeats in neuroblastoma: correlation with prognosis and other biological characteristics. Jpn J Cancer Res. 1992;83:159–64.PubMed
35.
Allsopp R, Vaziri H, Patterson C, Goldstein S, Younglai EV, Futcher AB, et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Nati Acad Sci USA. 1992;88:10114–8.CrossRef
36.
Maes L, Vanneste L, Vandamme K, Kalala JPO, Deridder L, Bekaert S, et al. Relation between telomerase activity, hTERT and telomere length for intracranial tumours. Oncol Rep. 2007;18:1571–6.PubMed
37.
Hakin-Smith V, Jellinek DA, Levy D, Carroll T, Teo M, Timperley WR, et al. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet. 2003;361:836–8.PubMedCrossRef
38.
Jang JS, Choi YY, Lee WK, Choi JE, Cha SI, Kim YJ, et al. Telomere length and the risk of lung cancer. Cancer Sci. 2008;99(7):1385–9.PubMedCrossRef
39.
Meeker AK, Argani P. Telomere shortening occurs early during breast tumorigenesis: a cause of chromosome destabilization underlying malignant transformation? J Mammary Gland Biol Neoplasia. 2004;9:285–96.PubMedCrossRef
40.
Svenson U, Nordfjäll K, Stegmayr B, Manjer J, Nilsson P, Tavelin BR, et al. Breast cancer survival is associated with telomere length in peripheral blood cells. Cancer Res. 2008;68(10):3618–23.PubMedCrossRef
41.
42.
Hackett JA, Greider CW. Balancing instability: dual roles for telomerase and telomere dysfunction in tumorigenesis. Oncogene. 2002;21:619–26.PubMedCrossRef
43.
44.
O’Sullivan J, Risques RA, Mandelson MT, Chen L, Brentnall TA, Bronner MP, et al. Telomere length in the colon declines with age: a relation to colorectal cancer? Cancer Epidemiol Biomarkers Prev. 2006;15(3):573–7.PubMedCrossRef
45.
Chen HJ, Liang CL, Lu K, Lin JW, Cho CL. Implication of telomerase activity and alternations of telomere length in the histologic characteristics of intracranial meningiomas. Cancer. 2000;89:2092–8.PubMedCrossRef
46.
Morii K, Tanaka R, Onda K, Tsumanuma I, Yoshimura J. Expression of telomerase RNA, telomerase activity, and telomere length in human gliomas. Biochem Biophys Res Commun. 1997;239:830–4.PubMedCrossRef
47.
Chen HJ, Cho CL, Liang CL, Chen L, Chang HW, Lu K, et al. Differential telomerase expression and telomere length in primary intracranial tumors. Chang Gung Med J. 2001;24(6):352–60.PubMed
48.
Maes L, Kalala JP, Cornelissen R, Ridder LD. Telomerase activity and hTERT protein expression in meningiomas: an analysis in vivo versus in vitro. Anticancer Res. 2006;26(3):2295–300.PubMed
Metadata
Title
Alterations of telomere length in human brain tumors
Authors
Majid Kheirollahi
Masoud Mehrazin
Naser Kamalian
Parvin Mehdipour
Publication date
01-09-2011
Publisher
Springer US
Published in
Medical Oncology / Issue 3/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9506-3

Other articles of this Issue 3/2011

Medical Oncology 3/2011 Go to the issue

Original Paper

Chemotherapy use and risk of bone marrow suppression in a large population-based cohort of older women with breast and ovarian cancer

Original Paper

Simultaneous over activation of EGFR, telomerase (h TERT), and cyclin D1 correlates with advanced disease in larynx squamous cell carcinoma: a tissue microarray analysis

OriginalPaper

Anti-cancer effects of 20(S)-protopanoxadiol on human acute lymphoblastic leukemia cell lines Reh and RS4;11

Original Paper

Temozolomide/PLGA microparticles: a new protocol for treatment of glioma in rats

Original paper

Effect of heat shock protein-90 (HSP90) and vascular endothelial growth factor (VEGF) on survival in acute lymphoblastic leukemia: an immunohistochemical study

Original Paper

Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits